65,437 trials
Ankylosing Spondylitis
Primary: Change From Baseline in Participant's Assessment of Global Pain Intensity at Week 6 — -23.8; -27.1 mm — p=0.0085
Meningococcal Meningitis · Tetanus · Diphtheria
Primary: Number of Participants With Antibodies Against Diphtheria and Tetanus at ≥ 1.0 IU/mL After DAPTACEL Vaccination — 249; 238; 246; 236 Participants
Influenza
Primary: Number of Participants With Local and Systemic Symptoms Post Vaccination 1 (Day 0) — 0; 13; 2; 3 participants
Cholangitis
Primary: Number of Participants With Cholangitis — 5; 5 participants — p=<0.05
Leiomyoma · Uterine Fibroids · Uterine Neoplasms
Primary: Number of Participants With Fibroid Devascularization Measured by Contrast Enhanced Magnetic Resonance Imaging (MRI) — 29; 29 participants
Smoking
Primary: Preoperative Carbon Monoxide Levels
Osteoarthritis of the Knee
Primary: Occurrence of Systemic and Local Adverse Events Following a Single or Repeat Intra-articular Injection of Gel-200 — 68; 43 participants — p=>0.1
Healthy
Primary: Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-t)] — 463.41; 498.87 ng*hr/mL
Chronic Obstructive Pulmonary Disease
Primary: Peak Inspiratory Capacity Assessed With Spirometry in the 4 Hours After Treatment — 2.705; 2.630; 2.557 Liters
Carotid Artery Disease
Primary: Composite of Major Adverse Events (MAE) Defined as Center-reported and Clinical Events Committee (CEC) Adjudicated Death, Stroke, and Myocardial Infarction (MI) — 47…
Chronic Obstructive Pulmonary Disease
Primary: Incidence of Adverse Events — 13; 17 Participants
Chronic Obstructive Pulmonary Disease
Primary: Trough Forced Expiratory Volume in 1 Second (FEV1) After 12 Weeks of Treatment — 1.49; 1.35 Liters
Chronic Obstructive Pulmonary Disease
Primary: Trough Forced Expiratory Volume in 1 Second (FEV1) 24 Hours Post-dose at the End of the Study (Week 12 + 1 Day, Day 85) — 1.38; 1.26 Liters
Asthma
Primary: Trough Forced Expiratory Volume in 1 Second (FEV1) After 2 Weeks of Treatment — 2.50; 2.52; 2.59; 2.54 Liters
Asthma
Primary: Percentage of Patients With at Least 1 Adverse Event During the 26 Weeks of the Study — 54.9; 66.4; 67.3 Percentage of patients